The sharp rise in cases of Non-alcoholic fatty liver disease is fast becoming one of the major concerns for hepatologists worldwide. This comprehensive clinical guide explains how to diagnose NAFLD and manage patients according to the best standards of care. Contributors from the world's leading institutions concentrate on patient care, drawing on their extensive experience.
Table of contents
1 What is NAFLD, and why is it important?
Geoffrey C Farrell, Arthur J McCullough and Christopher P. Day
2 NAFLD in the community.
3 Pathology of non-alcoholic fatty liver disease.
Elizabeth M. Brunt and David E. Kleiner
4 The natural history of NAFLD.
5 Emerging concepts on pathogenesis of NASH.
Isabelle A. Leclercq
6 Diabetes and NAFLD: why is the connection important?
7 NAFLD and cardiovascular risk factors: implications for vascular disease.
8 A primary care perspective of fatty liver: diagnosis, management, prescribing,
and when to refer.
Shivakumar Chitturi and Geoffrey C. Farrell
9 Imaging of non-alcoholic fatty liver disease.
Takeshi Yokoo, An Tang and Claude Sirlin
10 Non-invasive methods to determine severity of NAFLD/NASH.
Vincent W-S Wong and Henry L-Y Chan
11 Fatigue, quality of life and psychosocial issues for people with NAFLD.
Julia L Newton and James Frith
12 Physical activity and cardiovascular fitness in patients with NAFLD: clinical
importance and therapeutic implications.
Ingrid J Hickman, Nuala M. Byrne and Graeme A Macdonald
13 NAFLD, obesity and bariatric surgery.
14 Genetic predisposition to NAFLD and NASH. Implications for pathogenesis,
diagnosis, prevention and management.
Quentin M. Anstee, Ann K. Daly and Christopher P. Day
15 NAFLD in children.
Ariel E. Feldstein
16 The pointy end of the NAFLD iceberg: cirrhosis, portal hypertension, and
Jonathon W Schwake, Dawn M Torres and Stephen A Harrison
17 Non-alcoholic fatty liver disease, hepatocellular cancer and other cancers.
Janine Graham and Helen L. Reeves
18 NAFLD in Chinese and South Asian people.
Jia-Horng Kao, Deepak Amarapurkar and Jian-Gao Fan
19 Non-alcoholic fatty liver disease in Japan.
Takeshi Okanoue, Kohichiroh Yasui and Yoshito Itoh
20 Non-alcoholic fatty liver disease in South America and hispanic people.
Helma Pinchemel Cotrim and Carla Daltro
21 Alcohol in non-alcoholic fatty liver disease. An oxymoron or a new standard
Achuthan Sourianarayanane, Srinivasan Dasarathy and Arthur J. McCullough
22 Dietary factors in pathogenesis and care of patients with fatty liver disease.
Giulio Marchesini, Rebecca Marzocchi, Anna S. Sasdelli, Cristiana Andruccioli and Silvia Di Domizio
23 Metabolic factors and steatosis in patients with hepatitis B and C.
24 Drug therapy for NASH: insulin sensitizing agents (metformin and thiazolidinediones).
Mohammad S. Siddiqui and Arun J. Sanyal
25 Hepatoprotectants against fatty liver disease: antioxidants, ursodeoxycholic
acid, and herbal medicines.
Anne Catherine Bürgi and Jean-François Dufour
26 Lipid modifiers and NASH: statins, ezetimibe, fibrates and other agents.
Giovanni Musso, Federica Molinaro, Elena Paschetta, Roberto Gambino and Maurizio Cassader